Anthera Pharma (ANTH) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year Financial Results
March 10, 2016 8:37 AM ESTSOLUTION clinical study of oral Sollpura enrollment to begin soon in EuropeData from BRIGHT-SC study in IgA nephropathy planned for Q2 2016Addition of Craig Thompson as President and Chief Operating OfficerAppointment of Dr. James Pennington to Interim Chief Medical Officer
HAYWARD, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2015.
Recent Developments and Business Highlights:
Clinical Development
... More